Fibroblast growth factor 21 inhibited inflammation and fibrosis after myocardial infarction via EGR1

Jiamin Li1, Liling Gong1, Ruijie Zhang1

  • 1Department of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, Harbin, 150081, China.

Insights

Fibroblast growth factor 21 (FGF21) reduces cardiac inflammation and fibrosis after heart attack. FGF21 works by regulating the FGFR-EGR1 pathway, improving heart remodeling and function.

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Molecular Cardiology

Background:

  • Myocardial fibrosis following myocardial infarction (MI) contributes to adverse ventricular remodeling.
  • Fibroblast growth factor 21 (FGF21) is implicated in cardiovascular and metabolic diseases, but its role in post-MI cardiac inflammation and fibrosis is unclear.

Purpose of the Study:

  • To investigate the therapeutic effects of FGF21 on cardiac inflammation and fibrosis post-MI.
  • To elucidate the underlying molecular mechanisms of FGF21 action in the injured heart.

Main Methods:

  • Adult male Sprague-Dawley rats underwent MI and were treated with recombinant human basic FGF21 (rhbFGF21).
  • Cardiac function was assessed via echocardiography.
  • Cardiac inflammation and fibrosis were evaluated using histological staining (hematoxylin-eosin and Masson's trichrome).
  • The role of FGF receptors (FGFRs) and the early growth response protein 1 (EGR1) pathway was examined.

Main Results:

  • rhbFGF21 administration improved cardiac function and reduced cardiac inflammation and fibrosis.
  • FGF21 treatment led to decreased expression of inflammatory and fibrosis-related factors.
  • Blocking FGFRs abolished the beneficial effects of FGF21.
  • Oxidative stress-induced downregulation of EGR1 was identified as a key mechanism, contributing to reduced inflammation and fibrosis.

Conclusions:

  • FGF21 effectively suppresses cardiac inflammation and fibrosis in post-MI hearts.
  • The therapeutic effects of FGF21 are mediated through the FGFR-EGR1 signaling pathway.
  • FGF21 represents a potential therapeutic target for mitigating adverse cardiac remodeling after myocardial infarction.

Related Concept Videos

Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.3K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
77
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K